Jayadev, Suman, MD – M3D PhD Program

Dr. Suman Jayadev

Claim this profile

University of Washington

Studies Dementia
Studies Alzheimer's Disease
6 reported clinical trials
11 drugs studied

Area of expertise

1Dementia
Suman Jayadev has run 5 trials for Dementia. Some of their research focus areas include:
APP positive
PSEN1 positive
PSEN2 positive
2Alzheimer's Disease
Suman Jayadev has run 5 trials for Alzheimer's Disease. Some of their research focus areas include:
APP positive
PSEN1 positive
PSEN2 positive

Affiliated Hospitals

Image of trial facility.
University Of Washington
Image of trial facility.
University Of Washington Department Of Neurology

Clinical Trials Suman Jayadev is currently running

Image of trial facility.

Gantenerumab

for Alzheimer's Disease

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Image of trial facility.

Remternetug

for Alzheimer's Disease

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting0 awards Phase 2 & 32 criteria

More about Suman Jayadev

Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Suman Jayadev has experience with
  • E2814
  • Gantenerumab
  • Lecanemab
  • Solanezumab
  • Placebo
  • PTC518

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Suman Jayadev specialize in?
Is Suman Jayadev currently recruiting for clinical trials?
Are there any treatments that Suman Jayadev has studied deeply?
What is the best way to schedule an appointment with Suman Jayadev?
What is the office address of Suman Jayadev?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security